Drug
RP A501
RP A501: highest development phase Phase 2, developed by Rocket Pharmaceuticals. 2 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Rocket Pharmaceuticals
Trials
| Drug | Phase | Indication |
|---|---|---|
| RP-A501 NCT06092034 | Phase 2 | Danon Disease |
| RP-A501 NCT03882437 | Phase 1 | Danon Disease |
Latest
No recent events.
Follow RP A501 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.